Eptinezumab

證據等級: L5

預測適應症: 10 個

Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura

One-Sentence Summary

Eptinezumab (Vyepti) is an anti-CGRP monoclonal antibody approved by the FDA for preventive treatment of episodic and chronic migraine in adults. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura (IHS 1.2.2, formerly basilar-type migraine), with 0 clinical trials and 8 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Preventive treatment of episodic and chronic migraine
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.94%
Evidence Level	L3
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on information from the collected literature, Eptinezumab is an intravenous monoclonal antibody that directly targets calcitonin gene-related peptide (CGRP) — a potent vasodilatory neuropeptide abundantly expressed in the trigeminal-vascular axis. By binding to circulating CGRP and blocking its interaction with the CGRP receptor, eptinezumab suppresses neurogenic inflammation and vasodilation in the trigeminovascular system, which is the core pathway underlying migraine attacks.

Migraine with brainstem aura (IHS 1.2.2) is a specific subtype of migraine with aura in which the aura symptoms originate from brainstem structures — presenting as vertigo, tinnitus, diplopia, dysarthria, or ataxia. Since CGRP is expressed throughout brainstem nuclei involved in trigeminovascular signalling (including the trigeminal nucleus caudalis), the mechanistic basis for eptinezumab's potential efficacy in this subtype is biologically plausible and directly parallel to its established effect in broader migraine prevention.

The most directly relevant evidence is a 2022 post-hoc subgroup analysis of the Phase 3 PROMISE-1 and PROMISE-2 trials (PMID 35302389), which examined eptinezumab specifically in patients with self-reported aura and confirmed favourable efficacy and safety. While this does not constitute an independent RCT targeting the brainstem aura subtype, it provides the strongest available indirect evidence. The FDA's approved broad migraine prevention indication implicitly covers aura subtypes, but no dedicated trial has enrolled patients specifically with migraine with brainstem aura.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35302389	2022	Post-hoc RCT Subgroup	Cephalalgia	Post-hoc analysis of PROMISE-1 and PROMISE-2: eptinezumab demonstrated efficacy and safety specifically in migraine patients with self-reported aura — most direct evidence for the predicted indication
40229719	2025	RCT	J Headache Pain	PACAP38-induced migraine attacks occur independently of CGRP signalling; contextualises mechanistic scope and limits of anti-CGRP therapies including eptinezumab
40341526	2025	Observational	Headache	Two cases of genetic migraine syndromes (including chronic migraine with visual aura) showing clinically meaningful response to CGRP antagonist treatment
35268319	2022	Case Report + Review	J Clin Medicine	Anti-CGRP mAbs including eptinezumab may reduce migraine aura frequency; postulated mechanism via inhibition of cortical spreading depression-related CGRP release
40191903	2025	Case Report	Rev Neurol	IV eptinezumab successfully managed wearing-off effect in a patient with chronic migraine with aura refractory to two subcutaneous anti-CGRP antibodies
30725283	2019	Review	Handb Exp Pharmacol	Foundational review establishing CGRP as the central mediator in the trigeminovascular cascade; covers aura-associated subtypes and CNS involvement
32699706	2020	Review	Cureus	CGRP antagonists (including eptinezumab) effective across episodic and chronic migraine; pathophysiology review covering aura and autonomic features
33550872	2021	Review	Pain Management	Contextualises eptinezumab among the four approved anti-CGRP preventive therapies; summarises PROMISE trial outcomes and drug class characteristics

Singapore Market Information

Eptinezumab is currently not registered with the Health Sciences Authority (HSA) in Singapore. No product authorisations have been issued and no licences are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic rationale is directly compelling — migraine with brainstem aura shares the identical CGRP-dependent trigeminovascular pathway targeted by eptinezumab, and a post-hoc analysis of two large Phase 3 RCTs specifically confirms efficacy in patients with aura. However, the absence of a dedicated trial for the brainstem aura subtype, combined with no Singapore registration, means clinical deployment requires additional safeguards before proceeding.

To proceed, the following is needed:

Obtain full prescribing information (US FDA label for Vyepti / eptinezumab) to document contraindications, key warnings, and cardiovascular safety considerations
Confirm whether patients with migraine with brainstem aura (basilar-type migraine) were explicitly included or excluded in the PROMISE-1 and PROMISE-2 protocols — some legacy trial exclusion criteria banned basilar-type migraine due to historical stroke concerns
Conduct a dedicated prospective study or real-world registry to collect outcome data specifically for the brainstem aura subtype
Evaluate HSA regulatory pathway for Singapore market entry (import licence or full registration)
Assess cardiovascular risk profile of the target population, given that anti-CGRP therapy warrants caution in patients with recent cardiovascular events
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.